REDWOOD CITY, Calif., Feb. 17, 2025 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today provided guidance on its financial results for the third quarter of fiscal 2025 year and (unaudited) ended December 31, 2024.
Tag: biotricity
Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform
REDWOOD CITY, Calif. and BELFAST, Northern Ireland, Jan. 15, 2025 /PRNewswire/ — Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing technology, have joined forces to create one of the most advanced, device-neutral…
Biotricity Achieves Positive Free Cash Flow Milestone
First Time in the Company’s History REDWOOD CITY, Calif., Dec. 3, 2024 /PRNewswire/ — Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced achieving…
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the second quarter of fiscal 2025 year and (unaudited) ended September 30, 2024.
Biotricity Delivers Bioheart, A Groundbreaking Consumer Heart Monitor
Continuous monitoring device with advanced features and analytics to deliver personalized insights directly to the smartphone REDWOOD CITY, Calif.–(BUSINESS WIRE)–Biotricity, Inc. (NASDAQ:BTCY), a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions, today announced the availability of Bioheart, a direct-to-consumer heart monitor that offers the same continuous heart monitoring technology […]
Biotricity Unveils “Biokit” with 3 Personal Medical Devices to Expand into Cardiac Disease Management
Company Expects New Personal Medical Device Kit to be available to customer by early 2022 REDWOOD CITY, CA / ACCESSWIRE / September 14, 2021 / Biotricity Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it has developed a personal medical device kit, Biokit, a bundled home-use set […]
Biotricity CEO Discusses Calculated Growth Strategy in Audio Interview with SmallCapVoice.com
AUSTIN, Texas, March 16, 2021 (GLOBE NEWSWIRE) — SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Waqaas Al-Siddiq, CEO of Biotricity Inc. (OTCQB: BTCY) (“the Company”), a modern medical technology company delivering disruptive solutions to the multi-billion-dollar cardiac monitoring and diagnostic market. Biotricity’s flagship Bioflux® product […]
Biotricity Announces New Solution for Personal Heart Management with Bioheart
Bioheart comfortably and continuously monitors daily activities and provides advanced heart performance data in a user-friendly format LAS VEGAS, Jan. 11, 2021 (GLOBE NEWSWIRE) — CES – Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced the upcoming release of Bioheart, a personal heart monitor. Designed for individuals diagnosed with or at risk for cardiovascular disease, Bioheart continuously […]
Biotricity Submitted 510(k) U.S. FDA Filing for Biotres
Biotres is a compact and discreet 3 channel holter solution REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it made a 510(k) submission to the U.S. Food and Drug Administration (FDA), on December 31 2020, for Biotres. The company expects this process to take […]
Biotricity Prepares 510(k) FDA Filing for Biotres
Required lab testing complete for Biotres a novel holter patch product REDWOOD CITY, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, announced today that it has completed required lab testing and is completing its 510(k) FDA filing for its latest potential product […]